BioPharmSignal logoBioPharmSignal

Biotech News

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences (RNA)Avidity Biosciences2026-06-25 13:46 ESTFDA / regulatory

RNA (RNA) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is rna.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences to Participate in Upcoming Investor Conference

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Announces Expected Record Date for Spin-Off

RNAAvidity Biosciences2026-06-25 13:46 EST

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

RNAAvidity Biosciences2026-06-25 13:46 EST

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

RNAAvidity Biosciences2026-06-25 13:46 EST

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Avidity Biosciences

Avidity Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

RNAAvidity Biosciences2026-06-26 05:03 EST

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

RNAAvidity Biosciences2026-06-26 05:03 EST

Avidity Biosciences to Participate in Upcoming Investor Conference

RNAAvidity Biosciences2026-06-26 05:03 EST

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

RNAAvidity Biosciences2026-06-26 05:03 EST

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

RNAAvidity Biosciences2026-06-26 05:03 EST

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States